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Background: The aim of this study was to evaluate the clinical manifestations and prevalence of familial
Mediterranean fever (FMF) in Japanese patients with unexplained fever and rheumatic manifestations.
Methods: We enrolled 601 patients with unexplained fever or suspected FMF throughout Japan between 2009 and
2015. Patients were divided into three groups according to Tel Hashomer criteria: sure FMF, probable FMF, and
non-FMF patients, including definitive rheumatic diseases. Mutation detection in exons 1, 2, 3, and 10 of the FMF
gene MEFV was performed by direct sequencing.
Results: A total of 192 patients (31.9 %) were diagnosed with FMF according to FMF diagnostic criteria. These
could be divided into sure FMF (56.3 %, n = 108) and probable FMF (43.7 %, n = 84) patients. Fever, abdominal
symptoms, and thoracic symptoms were significantly more common in FMF than non-FMF patients. Among FMF
patients, 26 (13.5 %) had concomitant rheumatic diseases. Most FMF patients (94.3 %, 181/192) carried at least
one MEFV mutation. Allele frequencies of M694I (13.5 % vs 0 %) and E148Q (39.1 % vs 24.8 %) mutations were
significantly higher in FMF compared with healthy subjects. Allele frequencies of common MEFV mutations in
FMF patients were M694I (13.5 %), P369S (8.6 %), R408Q (8.1 %), G304R (2.9 %), R202Q (4.4 %), E148Q (39.1 %),
L110P (11.7 %), and E84K (3.1 %). Patients with a sure FMF phenotype had a higher frequency of MEFV exon 10
mutation (M694I) and a lower frequency of MEFV exon 3 mutations (P369S, R408Q) compared with those with a
probable FMF phenotype.
Conclusion: The high prevalence of FMF in Japanese patients with unexplained fever was confirmed in the present
study. FMF should be suspected in cases of unexplained fever or non-specific rheumatic manifestations, and
mutational analysis of MEFV could be useful to predict the clinical phenotypes of FMF in Japan.
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Familial Mediterranean fever (FMF) is an autosomal re-
cessive disorder characterized by short, recurrent bouts
of fever [1]. The recurrent episodes of fever and systemic
inflammation, which last a few days and commonly ap-
pear during pre-adolescence, are accompanied by peri-
tonitis, arthritis, pleurisy, and skin manifestations [2].* Correspondence: migitakiyoshi@gmail.com
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clinical signs. It is prevalent in Mediterranean and
Middle Eastern populations [3], where clinical diagnosis
has been prompt, but non-Mediterranean FMF patients
have also been reported [4]. Although considered a rare
disease, it is possible that its diagnosis has been delayed
in some countries such as Japan [5].
Molecular genetic diagnostic testing is often used to
provide some information on FMF diagnosis [6]. How-
ever, a crucial issue for genetic counseling is that some
patients presenting with manifestations of sure FMF are
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toms confirms the disease analysis, but it is not uncom-
mon for no mutated alleles or only a single mutated
allele to be detected, even in Mediterranean FMF pa-
tients [8]. Moreover, in Japanese FMF patients, MEFV
exon 10 mutations are usually associated with sure dis-
ease phenotypes, even in heterozygous carriage [9]. A
high proportion of asymptomatic carriers of MEFV exon
2 or 3 variants is also observed [10, 11].
This observational study was performed to determine
the actual prevalence of FMF in Japanese patients with un-
explained fever and to elucidate its clinical characteristics.
We also analyzed the implications of these MEFV variants
on the clinical picture of Japanese patients with unex-
plained fever or non-specific rheumatic manifestations.
Methods
Design, setting, patients, and measurements
The study was conducted at the Clinical Research
Center of Nagasaki Medical Center, Japan. Patients with
unexplained fever were recruited consecutively from
those treated and followed up in the rheumatology de-
partment of participating hospitals. Unexplained fever
was defined as a temperature above 38 °C that lasts for
3 weeks including recurrent episodes of fever without
diagnosis after standardized history-taking, physical
examination, and obligatory investigation. These subjects
included the newly diagnosed FMF patients in the previ-
ously performed multi-centric survey for FMF [12]. The
study comprised 601 patients (216 males, 385 females,
mean age 44.3 ± 20.2 years). On the basis of Tel Hashomer
criteria [13], patients were divided into three groups: sure
FMF—certain clinical diagnosis in the presence of two
major criteria or one major and two minor criteria; prob-
able FMF—clinical diagnosis considered probable in the
presence of one major and one minor criterion or two
minor criteria; and non-FMF—clinical diagnosis con-
sidered unlikely in the presence of only one minor and no
major criteria. Clinical manifestations of FMF, including
characteristics of febrile episodes (duration and fre-
quency), and the presence of serositis (chest or abdominal
pain), arthritis, myalgia, and erysipelas-like rash was docu-
mented. Demographic data (including gender, consan-
guinity of parents, familial history, and age of onset of
inflammation signs) and main clinical data (including
fever, thoracic, abdominal, articular, cutaneous signs, dur-
ation and frequency of episodes, presence of amyloidosis,
and response to colchicine) were recorded by the doctor
using a standard form. Response to colchicine was defined
as complete, incomplete, or absent.
Mutational analysis
Blood samples (2 ml) were collected from all subjects.
Genomic DNA was extracted from whole blood usingthe Wizard® Genomic DNA Purification Kit (Promega,
USA). Mutational analysis was performed by direct
DNA sequencing. Polymerase chain reaction (PCR)
amplification was performed for each MEFV exon, as
described previously [9]. A total of 27 PCR products per
patient were purified using ExoSAP-IT (GE Healthcare
Japan, Tokyo, Japan) and sequenced directly using
specific primers and BigDye Terminator v1.1 (Applied
Biosystems, Tokyo, Japan). The control group for MEFV
genotyping consisted of 105 gender-matched Japanese
healthy subjects (44 men and 61 women). The mean ± SD
age was 44.2 ± 11.5 years.
Statistical analyses
Data were analyzed using SPSS software (SPSS Inc.,
Chicago, IL, USA). Results were expressed as the
mean ± standard deviation (SD) for continuous variables.
For quantitative data, the Mann–Whitney U rank-sum
test compared two independent groups. Comparisons for
categorical variables were evaluated using the chi-square
test (or Fisher’s exact test when appropriate). Adjustment
for multiple comparisons was performed using the
Bonferroni method. Pc values were calculated by multiply-
ing the p value by the number of alleles tested.
Results
Patient demographic data
Ten patients were excluded from the study (Fig. 1). The
main reasons for exclusion were the absence of periodic
fever syndrome (drug fever, infections, and neoplastic
diseases). At the time of analysis, the mean patient age
was 44.3 ± 20.2 years (range 0–94 years) and the mean
age of the onset of symptoms was 36.3 ± 19.7 years
(range 1–94 years). The main clinical characteristics of
the 601 patients were as follows: 385 patients were
female (64.1 %), fever was observed in 482 (80.2 %), ab-
dominal symptoms in 163 (27.1 %), thoracic signs in 75
(12.5 %), arthritis signs in 345 (57.4 %), and amyloidosis
in 22 (3.7 %). On the basis of Tel Hashomer criteria, 192
patients (31.9 %) were diagnosed with FMF, of whom
108 had typical FMF (56.3 %) and 84 had incomplete
FMF (43.7 %). The remaining 409 patients (68.1 %) were
classified as non-FMF patients, including two patients
with suspected tumor necrosis factor receptor associated
periodic syndrome (TRAPS) and two patients with peri-
odic fever, aphthous stomatitis, pharyngitis, and adenitis
syndrome (PFAPA) (Fig. 1). As shown in Fig. 1, among
non-FMF patients, 118 patients had established rheum-
atic diseases (rheumatoid arthritis, n = 35; systemic lupus
erythematosus, n = 19; Behçet's disease, n = 17; gout,
n = 12; inflammatory myopathies, n = 7; mixed connective-
tissue disease, n = 4; psoriatic arthritis, n = 4; remitting sero-
negative symmetrical synovitis with pitting edema, n = 3;
Henoch-Schonlein purpura, n = 3; vasculitis syndrome,
Fig. 1 Flow diagram of patient enrollment
Table 1 Comparisons of clinical features of between FMF and
non-FMF
FMF Non-FMF
n = 192 n = 409 p
Male/female 83/109 133/276 0.011
Age at onset (years), mean ± SD 30.4 ± 39.4 39.4 ± 20.3 <0.0001
Fever 184 (95.8 %) 298 (72.9 %) <0.0001
Frequencies of febrile attack
(per month), mean ± SD
1.06 ± 0.92 0.97 ± 1.11 0.020
Duration of fever attack (days),
mean ± SD
3.7 ± 4.0 6.7 ± 8.4 0.001
Abdominal pain 77 (40.1 %) 86 (21.0 %) <0.0001
Thoracic pain 51 (26.6 %) 24 (5.9 %) <0.0001
Arthritis 108 (56.3 %) 237 (57.9 %) 0.695
Erysipelas-like erythema 34 (17.7 %) 43 (10.5 %) 0.014
AA amyloidosis 7 (3.6 %) 15 (3.7 %) 0.989
Family history of periodic fever 39 (20.3 %) 25 (6.1 %) <0.0001
Rheumatic diseases 26 (13.5 %) 186 (45.5 %) <0.0001
Values are shown as n (%) unless otherwise indicated. AA amyloid A,
FMF familial Mediterranean fever
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n = 2; Sjögren's syndrome, n = 2; Reiter's syndrome, n = 1;
Crowned dens syndrome, n = 1; relapsing polychondritis,
n = 1; spondylarthritis, n = 1; systemic sclerosis, n = 1).
Additionally, among non-FMF patients, 68 patients were
finally diagnosed as having rheumatic diseases (Behçet's
disease, n = 11; rheumatoid arthritis, n = 9; inflammatory
myopathies, n = 7; vasculitis syndrome, n = 7; Sjögren's
syndrome, n = 6; systemic lupus erythematosus, n = 6;
palindromic rheumatism, n = 5; mixed connective-tissue
disease, n = 4; gout, n = 3; CREST syndrome, n = 2; anky-
losing spondylitis, n = 2; adult onset Still's disease, n = 1;
Caplan's syndrome, n = 1; IgG4-related disease, n = 1;
SAPHO syndrome, n = 1; psoriatic arthritis, n = 1; eosino-
philic fasciitis, n = 1). Among the remaining non-FMF
patients, 37 patients were finally diagnosed with non-
rheumatic diseases (amyloidosis, n = 5; myelodysplastic
syndromes, n = 4; Castleman's disease, n = 4; undifferenti-
ated arthritis, n = 3; viral infection, n = 3; Sweet's disease,
n = 2; Kikuchi's disease, n = 2; hemophagocytic syndrome,
n = 2; chronic thyroiditis, n = 2; idiopathic thrombocytope-
nic purpura, n = 1; alcoholic hepatitis, n = 1; Wilson's
disease, n = 1; cryoglobulinemia, n = 1; Crohn's disease,
n = 1; recurrent stomatitis, n = 1; malignant lymphoma,
n = 1; reactive lymphadenitis, n = 1; non-tuberculous
mycobacterial disease, n = 1; interstitial nephritis, n = 1).
FMF patients had a shorter duration of febrile attack
and higher frequencies of abdominal or thoracic symp-
toms and family history of periodic fever (Table 1). Col-
chicine was administered to 300 patients (sure FMF,86.1 %; probable FMF, 95.2 %; non-FMF patients,
31.1 %), and the response was higher in patients with
typical FMF (97.8 %) compared with those in the other
groups (non-FMF, 64.6 %). The response rates for colchi-
cine treatment were not significantly different between
subgroups of FMF classified by MEFV mutations
(Table 2).
Table 2 Clinical response to colchicine in FMF patients
Subgroups Response rate p
Sure vs Probable 91/93 (97.8 %) 74/80 (92.5 %) 0.095
(0.82 ± 0.40)* (0.84 ± 0.54)*
MEFV mutations (+) vs MEFV mutations (–) 154/162 (95.1 %) 11/11 (100 %) 0.585
M694I (+) vs M694I (–) 36/37 (97.3 %) 129/136 (94.9 %) 0.459
E148Q (+) vs E148Q (–) 109/115 (94.8 %) 56/58 (96.6 %) 0.461
Rheumatic diseases (+) vs Rheumatic diseases (–) 23/23 (100 %) 142/150 (94.7 %) 0.311
*Mean dose of colchicine, mg/day. FMF familial Mediterranean fever
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As shown in Table 3, short durations of fever, and thor-
acic and abdominal symptoms were more frequently ob-
served in sure FMF patients (2.2 ± 0.8 days) compared
with probable FMF patients (6.2 ± 5.5 days). Conversely,
arthritis was more frequently observed in probable FMF
patients compared with sure FMF patients. Among FMF
patients, 7 (3.6 %) had biopsy-proven amyloid A (AA)
amyloidosis (sure FMF, n = 6; probable FMF, n = 1).
Among non-FMF patients, 15 patients had AA amyloid-
osis and primary diseases were rheumatoid arthritis
(n = 10) and Crohn's disease (n = 1), whereas primary dis-
eases were not identified in four patients. The allele fre-
quencies of MEFV mutations between AA amyloidosis
patients with or without FMF are shown in Table 4. Only
the allelic frequency of M694I was significantly higher in
FMF patients with AA amyloidosis.
For the sure FMF patients, 13.0 % (14/108) had con-
comitant rheumatic diseases (rheumatoid arthritis, n = 6;Table 3 Comparisons of clinical features of patients with
different FMF phenotypes
Sure FMF Probable FMF
n = 108 n = 84 p
Male/female 51/57 32/52 0.205
Age at onset (years), mean ± SD 30.5 ± 17.4 30.3 ± 16.6 0.939
Fever 108 (100 %) 76 (90.5 %) 0.001
Frequencies of febrile attack
(per month), mean ± SD
1.11 ± 0.93 0.98 ± 0.90 0.309
Duration of fever attack (days),
mean ± SD
2.2 ± 0.8 6.2 ± 5.5 <0.0001
Abdominal pain 54 (50.0 %) 23 (27.4 %) 0.002
Thoracic pain 33 (30.6 %) 18 (21.4 %) 0.155
Arthritis 53 (49.1 %) 55 (65.5 %) 0.023
Erysipelas-like erythema 15 (13.9 %) 19 (22.6 %) 0.116
AA amyloidosis 6 (5.6 %) 1 (1.2 %) 0.110
Family history of periodic fever 26 (24.1 %) 13 (15.5 %) 0.142
Rheumatic diseases 14 (13.0 %) 12 (14.3 %) 0.790
Values are shown as n (%) unless otherwise indicated. AA amyloid A,
FMF familial Mediterranean feverSjögren's syndrome, n = 3; dermatomyositis complex, n = 2;
Behçet's disease, n = 1; adult onset Still's disease, n = 1;
Kawasaki disease, n = 1). In the probable FMF patients,
14.3 % (12/84) had concomitant rheumatic diseases
(systemic lupus erythematosus, n = 4; Sjögren's syndrome,
n = 3; rheumatoid arthritis, n = 2; Behçet's disease, n = 1;
palindromic rheumatism, n = 1; polymyositis, n = 1).
FMF patients with rheumatic diseases had a higher fre-
quency of arthritis episodes and an elderly onset of FMF.
Conversely, FMF patients without rheumatic diseases
had a higher frequency of abdominal pain and family
history of FMF (Table 5). No significant difference was
observed in the allele frequencies in MEFV mutations
between FMF patients with or without rheumatic dis-
eases (Table 6).
Allele frequencies of MEFV mutations in FMF and healthy
subjects
Distributions of MEFV genotypes in the FMF and non-
FMF groups are shown in Table 7. Table 8 shows the
allelic frequencies of MEFV mutations in the FMF and
non-FMF groups. Most FMF patients (94.3 %, 181/192)
carried at least one MEFV mutation. SignificantTable 4 Allelic frequencies of MEFV mutations of AA
amyloidosis patients with or without FMF
AA amyloidosis
FMF Non-FMF
2n = 14 2n = 30 p
Exon10 M694I 8 (57.1 %) 0 <0.0001
Exon3 R408Q 1 (7.1 %) 0 0.318
P369S 1 (7.1 %) 0 0.318
Exon2 G304R 0 1 (3.3 %) 0.682
R202Q 1 (7.1 %) 0 0.318
E148Q 5 (35.7 %) 5 (16.7 %) 0.1540
L110P 3 (21.4 %) 2 (6.7 %) 0.175
Exon1 E84K 0 1 (3.3 %) 0.682
Values are shown as n (%). Primary diseases of amyloid A (AA) amyloidosis in
non-familial Mediterranean fever (FMF) were rheumatoid arthritis (n = 10) and
Crohn's disease (n = 1)
Table 5 Comparisons of clinical features of patients with or






n = 26 n = 166 p
Male/female 4/22 79/87 0.002
Age at onset (years),
mean ± SD
39.3 ± 15.8 29.0 ± 16.8 0.006
Fever 24 (92.3 %) 160 (96.4 %) 0.296
Frequencies of febrile attack
(per month), mean ± SD
1.01 ± 0.59 1.06 ± 0.96 0.523
Duration of fever attack (days),
mean ± SD
3.0 ± 2.2 3.8 ± 4.1 0.359
Abdominal pain 3 (11.5 %) 74 (44.6 %) 0.001
Thoracic pain 4 (15.4 %) 47 (28.3 %) 0.165
Arthritis 21 (80.8 %) 87 (52.4 %) 0.007
Erysipelas-like erythema 3 (11.5 %) 31 (18.7 %) 0.281
AA amyloidosis 0 7 (4.2 %) 0.355
Family history of periodic fever 1 (3.8 %) 38 (22.9 %) 0.025
Values are shown as n (%) unless otherwise indicated. AA amyloid A,
FMF familial Mediterranean fever
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healthy subjects regarding the allelic frequencies of
mutations in MEFV exon 2 (E148Q, 39.1 % vs 24.8 %,
respectively) and exon 10 (M694I, 13.5 % vs 0 %,
respectively). However, there were no significant dif-








R408Q 8 (15.4 %) [2/26 (7.7 %)]
P369S 8 (15.4 %) [2/26 (7.7 %)]
R354Q 0
Exon2 G304R 3 (5.8 %) [0/26 (0 %)]
E225K 0
R202Q 3 (5.8 %)
E148Q 23 (44.2 %) [4/26 (15.4 %)]
P115R 0
L110P 8 (15.4 %) [0/26 (0 %)]
Exon1 E84K 1 (1.9 %)
R80H 0
Values are shown as n (%) [% of homozygote]. FMF familial Mediterranean fever, pcregarding the allelic frequencies of other mutations
(Table 9).MEFV mutations in FMF patients
Table 10 shows the allelic frequencies of MEFV muta-
tions according to the FMF disease phenotype.
Among FMF patients, the allelic frequencies of the
MEFV exon 10 mutation (M694I) were significantly
higher in sure FMF patients compared with probable
FMF patients, while the allelic frequencies of the
MEFV exon 3 mutations (P369S, R408Q) were sig-
nificantly lower in sure FMF patients compared with
probable FMF patients. No significant difference was
seen in the allele frequencies of other MEFV muta-
tions between FMF patients with or without rheum-
atic disease.Influence of MEFV mutation number on clinical
phenotype
Although FMF is considered an autosomal recessive dis-
ease, the presence of only a single mutation can often be
associated with the occurrence of FMF. We analyzed the
differences in clinical manifestations according to the
number of MEFV mutations. FMF patients with two or
more than two MEFV mutations had AA amyloidosis
and family history of periodic fever more frequently
compared with those with a single or no MEFV muta-
tions (Table 11).F patients with or without accompanying rheumatic diseases
Rheumatic diseases (–)
2n = 332 p pc
48 (14.5 %) [4/166 (2.4 %)] 0.185 2.7738
1 (0.3 %) 0.865 12.9687
1 (0.3 %) 0.865 12.9687
1 (0.3 %) 0.865 12.9687
23 (6.9 %) [0/166 (0 %)] 0.043 0.6419
25 (7.5 %) [0/166 (0 %)] 0.060 0.9050
1 (0.3 %) 0.865 12.9687
8 (2.4 %) [1/166 (0.6 %)] 0.176 2.6382
1 (0.3 %) 0.865 12.9687
14 (4.2 %) 0.411 6.1680
127 (38.3 %) [19/166 (11.4 %)] 0.411 6.1702
0
37 (11.1 %) [1/166 (0.6 %)] 0.377 5.6513
11 (3.3 %) 0.500 7.4946
0
corrected p value







n = 108 n = 84 n = 68 n = 118 n = 223
M694I/M694I 5 (4.6 %) 0 0 0 0
M694I/P751L 1 (0.9 %) 0 0 0 0
M694I/E148Q/E148Q 1 (0.9 %) 0 0 0 0
M694I/L110P/E148Q 8 (7.4 %) 0 0 0 0
M694I/E148Q 22 (20.4 %) 0 0 0 0
M694I/normal 10 (9.3 %) 0 0 0 0
G632/E148Q 0 1 (1.2 %) 0 0 0
R354Q/normal 0 1 (1.2 %) 0 0 0
P369S/R408Q 2 (1.9 %) 8 (9.5 %) 2 (2.9 %) 2 (1.7 %) 16 (7.2 %)
G304R/G304R 0 1 (1.2 %) 0 0 0
G304R/P369S/R408Q 0 0 0 0 1 (0.5 %)
G304R/normal 1 (0.9 %) 5 (6.0 %) 1 (1.5 %) 6 (5.1 %) 8 (3.6 %)
R202Q/R202Q 0 0 0 0 1 (0.5 %)
R202Q/P369S/R408Q 1 (0.9 %) 0 0 2 (1.7 %) 0
R202Q/normal 5 (4.6 %) 4 (4.8 %) 4 (5.9 %) 3 (2.5 %) 11 (4.9 %)
E225K/P369S/R408Q 0 1 (1.2 %) 0 0 0
E148Q/E148Q 3 (2.8 %) 4 (4.8 %) 2 (2.9 %) 4 (3.4 %) 2 (0.9 %)
E148Q/G304R/P369S/R408Q 1 (0.9 %) 0 1 (1.5 %) 0 0
E148Q/R202Q/P369S/R408Q 0 2 (2.4 %) 0 0 0
E148Q/R202Q 2 (1.9 %) 0 0 1 (0.9 %) 2 (0.9 %)
E148Q/E148Q/P369S/P369S/R408Q/R408Q 0 1 (1.2 %) 0 0 0
E148Q/E148Q/P369S/R408Q 1 (0.9 %) 2 (2.4 %) 0 0 2 (0.9 %)
E148Q/P369S/P369S/R408Q/R408Q 0 1 (1.2 %) 0 0 1 (0.5 %)
E148Q/P369S/R408Q 3 (2.8 %) 5 (6.0 %) 0 3 (2.5 %) 7 (3.1 %)
E148Q/P369S 0 1 (1.2 %) 0 0 1 (0.5 %)
E148Q/normal 15 (13.9 %) 16 (19.0 %) 10 (14.7 %) 26 (22.0 %) 44 (19.7 %)
P115R/normal 0 0 1 (1.5 %) 1 (0.9 %) 0
L110P/E148Q/E148Q/P369S/R408Q 0 1 (1.2 %) 0 1 (0.9 %) 1 (0.5 %)
L110P/E148Q/E148Q/P369S 0 0 0 1 (0.9 %) 0
L110P/E148Q/R202Q/P369S/R408Q 0 0 0 0 1 (0.5 %)
L110P/E148Q/P369S/R408Q 0 0 1 (1.5 %) 1 (0.9 %) 2 (0.9 %)
L110P/E148Q/P369S 0 1 (1.2 %) 0 0 3 (1.4 %)
L110P/E148Q/G304R 0 1 (1.2 %) 0 0 1 (0.5 %)
L110P/E148Q/R202Q 1 (0.9 %) 2 (2.4 %) 0 0 0
L110P/L110P/E148Q/E148Q 0 0 0 0 1 (0.5 %)
L110P/E148Q/E148Q 3 (2.8 %) 7 (8.3 %) 1 (1.5 %) 1 (0.9 %) 5 (2.2 %)
L110P/L110P/E148Q 1 (0.9 %) 0 0 0 0
L110P/E148Q 13 (12.0 %) 5 (6.0 %) 6 (8.8 %) 13 (11.0 %) 21 (9.4 %)
E84K/L110P/E148Q 0 1 (1.2 %) 0 1 (0.9 %) 0
E84K/G304R 0 1 (1.2 %) 0 0 0
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Table 7 MEFV genotypes in FMF or non-FMF patients (Continued)
E84K/E148Q 0 2 (2.4 %) 0 0 1 (0.5 %)
E84K/R410H 1 (0.9 %) 0 0 0 1 (0.5 %)
E84K/normal 3 (2.8 %) 4 (4.8 %) 1 (1.5 %) 1 (0.9 %) 6 (2.7 %)
R80H/normal 0 0 0 0 1 (0.5 %)
Normal 5 (4.6 %) 6 (7.1 %) 38 (55.9 %) 51 (43.2 %) 83 (37.2 %)
Values are shown as n (%). FMF familial Mediterranean fever
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This is a multicentric study into the prevalence of FMF
patients in Japan. FMF was diagnosed in a high number
of Japanese patients with unexplained fever or rheumatic
manifestations. Based on our findings, we propose that
FMF should be considered as a differential diagnosis for
patients with unexplained rheumatic symptoms, even in
the Japanese population. Other forms of recurrent her-
editary fever, such as TRAPS, appear to be rarer than
FMF, although genetic analysis for these diseases was
not routinely performed.
The clinical diagnosis of FMF is not easy [3]. It has
mainly been based on clinical signs, although MEFV
genetic analysis is useful in Japan [14]. It is conceivable
that the reported delay in diagnosis may result from the
low awareness of FMF in Japan because of its miscon-
ceived rarity. The detection of MEFV mutations with
high penetrance may help achieve a precise FMF diagno-
sis [15]. However, the observation of many heterozygous




2n = 216 2n = 168 2n = 136
Exon10 M694I 52 (24.1 %) 0 0
P751L 1 (0.5 %) 0 0
G632S 0 1 (0.6 %) 0
Exon3 R410H 1 (0.5 %) 0 0
R408Q 8 (3.7 %) 23 (13.7 %) 4 (2.9 %)
P369S 8 (3.7 %) 25 (14.9 %) 4 (2.9 %)
R354Q 0 1 (0.6 %) 0
Exon2 G304R 2 (0.9 %) 9 (5.4 %) 3 (1.8 %)
E225K 0 1 (0.6 %) 0
R202Q 9 (4.2 %) 8 (4.8 %) 4 (2.9 %)
E148Q 82 (38.0 %) 68 (40.5 %) 24 (17.6 %)
P115R 0 0 1 (0.7 %)
L110P 27 (12.5 %) 18 (10.7 %) 8 (5.9 %)
Exon1 E84K 4 (1.9 %) 8 (4.8 %) 1 (0.7 %)
R80H 0 0 0
Values are shown as n (%). FMF familial Mediterranean feverespecially in non-Mediterranean countries such as Japan,
suggests the involvement of other genetic or environ-
mental FMF susceptibility factors in disease suscep-
tibility [17, 18]. Additionally, MEFV variants with low
penetrance could be associated with clinical features that
resemble FMF [10, 11].
It is evident that the use of the genetic approach to
FMF diagnosis in patients with atypical clinical presenta-
tions has not been fully addressed. Of note, we identified
significant differences in the allele frequencies of MEFV
variants (M694I and E148Q) between FMF and non-
FMF patients in the present study. The diagnostic value
of MEFV exon 10 mutations has previously been estab-
lished [19]; however, MEFV exon 2 or 3 polymorphisms
were not thought to affect FMF occurrence [20, 21]. The
E148Q variant has been established as a polymorphism,
but some studies suggest that it is related to some
clinical manifestations of rheumatic diseases [22]. In our
study, the prevalence of this MEFV variant was increased










0 1 (0.2 %) 0
9 (3.8 %) 32 (7.2 %) 12 (5.7 %)
10 (4.2 %) 36 (8.1 %) 13 (6.2 %)
0 0 0
6 (2.4 %) 10 (2.2 %) 6 (2.9 %)
0 0 0
6 (2.5 %) 16 (3.6 %) 6 (2.9 %)
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1 (0.4 %) 0 0
18 (7.6 %) 36 (8.1 %) 15 (7.1 %)
2 (0.8 %) 8 (1.8 %) 2 (1.0 %)
0 1 (0.2 %) 0
Table 9 Comparisons of allelic frequencies of MEFV mutations
between FMF and healthy subjects
FMF Healthy subjects
2n = 384 2n = 210 p pc
Exon10 M694I 52 (13.5 %) 0 <0.0001 <0.0001
P751L 1 (0.3 %) 0 0.646 9.6970
G632S 1 (0.3 %) 0 0.646 9.6970
Exon3 R410H 1 (0.3 %) 0 0.646 9.6970
R408Q 31 (8.1 %) 12 (5.7 %) 0.289 4.3336
P369S 33 (8.6 %) 13 (6.2 %) 0.295 4.4222
R354Q 1 (0.3 %) 0 0.646 9.6970
Exon2 G304R 11 (2.9 %) 6 (2.9 %) 0.996 14.9378
E225K 1 (0.3 %) 0 0.646 9.6970
R202Q 17 (4.4 %) 6 (2.9 %) 0.343 5.1459
E148Q 150 (39.1 %) 52 (24.8 %) 0.0004 0.0065
P115R 0 0
L110P 45 (11.7 %) 15 (7.1 %) 0.077 1.1527
Exon1 E84K 12 (3.1 %) 2 (1.0 %) 0.077 1.1610
R80H 0 0
Values are shown as n (%). FMF familial Mediterranean fever, pc corrected
p value
Table 11 Clinical features of FMF patients with different
numbers of MEFV mutations
No. of MEFV mutations
Clinical manifestations ≥2 0 or 1
n = 117 n = 75 p
Male/female 52/65 31/44 0.671
Age at onset (years),
mean ± SD
28.3 ± 15.2 33.7 ± 19.2 0.097
Fever 113 (96.6 %) 71 (94.7 %) 0.383
Frequencies of febrile attack
(per month), mean ± SD
1.11 ± 0.97 0.97 ± 0.83 0.438
Duration of fever attack (days),
mean ± SD
3.1 ± 2.1 4.6 ± 5.6 0.201
Abdominal pain 51 (43.6 %) 26 (34.7 %) 0.218
Thoracic pain 36 (30.8 %) 15 (20.0 %) 0.099
Arthritis 69 (59.0 %) 39 (52.0 %) 0.342
Erysipelas-like erythema 17 (14.5 %) 17 (22.7 %) 0.150
AA amyloidosis 7 (6.0 %) 0 0.029
Family history of periodic fever 31 (26.5 %) 8 (10.7 %) 0.008
Rheumatic diseases 18 (15.4 %) 8 (10.7 %) 0.351
Values are shown as n (%) unless otherwise indicated. AA amyloid A,
FMF familial Mediterranean fever
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and genetic characteristics. The prevalence of MEFV exon
10 mutations and MEFV homozygous mutations was
lower compared with those in Western countries [23].
Contrary to the concept that FMF is caused by recessive
loss-of-function mutations, it is more likely that MEFVTable 10 Comparisons of allelic frequencies of MEFV mutations
of patients with sure FMF and probable FMF
Sure FMF Probable FMF
2n = 216 2n = 168 p pc
Exon10 M694I 52 (24.1 %) 0 <0.0001 <0.0001
P751L 1 (0.5 %) 0 0.563 8.4375
G632S 0 1 (0.6 %) 0.438 6.5625
Exon3 R410H 1 (0.5 %) 0 0.563 8.4375
R408Q 8 (3.7 %) 23 (13.7 %) 0.0004 0.0055
P369S 8 (3.7 %) 25 (14.9 %) 0.0001 0.0016
R354Q 0 1 (0.6 %) 0.438 6.5625
Exon2 G304R 2 (0.9 %) 9 (5.4 %) 0.011 0.1641
E225K 0 1 (0.6 %) 0.438 6.5625
R202Q 9 (4.2 %) 8 (4.8 %) 0.778 11.6771
E148Q 82 (38.0 %) 68 (40.5 %) 0.617 9.2482
P115R 0 0
L110P 27 (12.5 %) 18 (10.7 %) 0.589 8.8411
Exon1 E84K 4 (1.9 %) 8 (4.8 %) 0.104 1.5597
R80H 0 0
Values are shown as n (%). FMF familial Mediterranean fever, pc corrected
p valuemutations cause FMF by a gain-of-function model [24]. It
is conceivable that these genetic features contribute to the
increased proportion of patients with probable FMF. Add-
itionally, a genotype–phenotype relationship between the
MEFV exon 10 mutation and the sure FMF phenotype
was confirmed. Although clinical judgments still remain
crucial in FMF diagnosis, our data show that a molecular
approach to FMF diagnosis enables confirmation of typical
FMF cases or genotype–phenotype correlations.
In the present study, we defined a minor subgroup carry-
ing MEFV variants in whom a definitive diagnosis of FMF
was made in addition to pre-existing established rheumatic
diseases. These patients had periodic fever, serositis, or
synovitis that was not explained by the activities of primary
rheumatic diseases. Furthermore, these clinical manifesta-
tions were silenced by colchicine in the majority of pa-
tients. These findings suggest that an overlap between
FMF and established rheumatic diseases is not unusual. It
is well known that rheumatic diseases including lupus
often cause acute serositis. When FMF patients with these
rheumatic diseases showed laboratory data suggestive of
active primary rheumatic diseases, such as hypocomple-
mentemia or high titer of anti-ds-DNA antibody, these
manifestations seem to be caused by FMF-related serositis
[25]. Additionally, steroids have no beneficial effects in
FMF attacks. A response to adequate colchicine therapy
could confirm FMF [26], whereas steroid use has a benefit
in some autoinflammatory diseases, including AOSD [27].
These findings may provide valuable information on differ-
ential diagnosis for FMF and rheumatic diseases.
Migita et al. Arthritis Research & Therapy  (2016) 18:175 Page 9 of 10Conflicting evidence exists as to whether single MEFV
mutations are associated with the occurrence of other
inflammatory diseases [28]. MEFV has previously been
shown to be an independent modifier of the clinical mani-
festations of rheumatoid arthritis. Rabinovich et al. found
that rheumatoid arthritis patients carrying MEFV muta-
tions developed more severe disease than those with
multiple mutations [22], while Ayaz et al. reported that
juvenile idiopathic arthritis patients harboring MEFV
mutations presented with the polyarticular course with
detective arthritis [29]. These findings suggest that MEFV
mutations or polymorphisms, even in one allele, associate
with atypical clinical manifestations or subclinical inflam-
mation not attributable to the primary rheumatic disease.
It is tempting to speculate that, after the development of
rheumatic diseases, the presence of an MEFV mutation
modulates the clinical phenotype or contributes to the oc-
currence of FMF. No consensus has yet been demonstrated
to classify the E148Q variant as pathogenic or non-
pathogenic [30]. This sequence variant was described as a
disease-causing mutation with low penetrance [31]. On the
other hand, 50 % of E148Q homozygotes are asymptomatic
and there is high prevalence of this variant in the Japanese
population contrasting with a low FMF prevalence. E148Q
is insufficient to trigger FMF but may act as a disease
modifier [32]. In our study, Japanese FMF patients have a
higher prevalence of E148Q compared to healthy subjects.
Although the allele frequency of the E148Q variant is high
in the Japanese population, these data may suggest that
some Japanese patients with low-penetrance E148Q muta-
tion may develop FMF in combination with unknown en-
vironmental or other genetic factors.
Our present study has a number of limitations. One of
the main limitations of our study may be its hospital-based
nature. The prevalence of symptomatic or FMF-suspicious
individuals may be higher in those patients attending hos-
pital regularly. Also, we did not evaluate disease severity,
and there was insufficient follow-up of the long-term dis-
ease course, including the response to colchicine treat-
ment. Although participating hospitals were encouraged to
update patient files, these measures are not complete. The
regular screening for AA amyloidosis was not performed
in some institutes, which may alter the incidence of AA
amyloidosis in our subjects. The mean age of onset of FMF
patients in this study was 28.4 years, which seems to be
relatively older compared to the previous Japanese investi-
gations. A significant number of enrolments of adult pa-
tients with FMF may contribute to the more elderly onset
of FMF in this study.
Conclusions
Our data showed a high prevalence of FMF as well
as MEFV mutations in Japanese patients with unex-
plained fever. We suggest that a significant numberof FMF cases were included in Japanese patients
with unexplained fever. Mutational analysis of MEFV
should be considered in cases of unexplained fever
or non-specific rheumatic manifestations, even in
Japan.
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